SI2694075T1 - Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink - Google Patents

Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink

Info

Publication number
SI2694075T1
SI2694075T1 SI201230597A SI201230597A SI2694075T1 SI 2694075 T1 SI2694075 T1 SI 2694075T1 SI 201230597 A SI201230597 A SI 201230597A SI 201230597 A SI201230597 A SI 201230597A SI 2694075 T1 SI2694075 T1 SI 2694075T1
Authority
SI
Slovenia
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
zinc
Prior art date
Application number
SI201230597A
Other languages
English (en)
Slovenian (sl)
Inventor
Xiong Cai
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis, Inc. filed Critical Curis, Inc.
Publication of SI2694075T1 publication Critical patent/SI2694075T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201230597A 2011-04-01 2012-03-30 Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink SI2694075T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
EP12764605.7A EP2694075B1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
SI2694075T1 true SI2694075T1 (sl) 2016-07-29

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201230597A SI2694075T1 (sl) 2011-04-01 2012-03-30 Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
SI201231625T SI3111938T1 (sl) 2011-04-01 2012-03-30 Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201231625T SI3111938T1 (sl) 2011-04-01 2012-03-30 Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink

Country Status (29)

Country Link
US (7) US8710219B2 (enExample)
EP (2) EP2694075B1 (enExample)
JP (3) JP6242331B2 (enExample)
KR (2) KR101902325B1 (enExample)
CN (2) CN105461736B (enExample)
AU (1) AU2012236367B2 (enExample)
BR (1) BR112013025340B1 (enExample)
CA (1) CA2830822C (enExample)
CL (1) CL2013002823A1 (enExample)
CY (2) CY1117785T1 (enExample)
DK (2) DK2694075T3 (enExample)
EA (1) EA022434B9 (enExample)
ES (2) ES2577982T3 (enExample)
HR (2) HRP20160545T1 (enExample)
HU (2) HUE028910T2 (enExample)
IL (2) IL228588A (enExample)
LT (1) LT3111938T (enExample)
ME (2) ME02451B (enExample)
MX (1) MX340577B (enExample)
PE (1) PE20141382A1 (enExample)
PL (2) PL2694075T3 (enExample)
PT (2) PT2694075T (enExample)
RS (2) RS54903B1 (enExample)
SG (2) SG193563A1 (enExample)
SI (2) SI2694075T1 (enExample)
SM (2) SMT201900435T1 (enExample)
TW (1) TWI571469B (enExample)
WO (1) WO2012135571A1 (enExample)
ZA (2) ZA201307082B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54230B1 (sr) 2009-01-08 2015-12-31 Curis Inc. Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
ME02451B (me) 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
JP6051434B2 (ja) 2011-11-14 2016-12-27 イグニタ、インク． ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
ES2833473T3 (es) * 2015-04-21 2021-06-15 Chengdu Zenitar Biomedical Tech Co Ltd Derivados de purinil-N-hidroxil pirimidin formamida, método de preparación y uso de los mismos
WO2018015895A1 (en) * 2016-07-19 2018-01-25 National Institute Of Plant Genome Research Novel protein against fungal pathogens
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
US11406647B2 (en) * 2017-11-06 2022-08-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
MX2021002742A (es) 2018-09-11 2021-08-11 Curis Inc Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc.
EP3968215A1 (en) 2020-09-09 2022-03-16 Koninklijke Philips N.V. Determining target object type and position
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP4648628B2 (ja) 2002-03-13 2011-03-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
MY140390A (en) 2002-03-13 2009-12-31 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
PL214756B1 (pl) 2003-01-29 2013-09-30 Takeda Pharmaceutical Zwiazki tienopirymidynowe, kompozycja farmaceutyczna zawierajaca te zwiazki oraz ich zastosowanie
JP4993374B2 (ja) * 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
ES2553178T3 (es) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
CN101370791B (zh) 2006-01-19 2012-05-02 詹森药业有限公司 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物
AU2007206941B2 (en) 2006-01-19 2012-09-13 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2347187T3 (es) 2006-04-26 2010-10-26 F. Hoffmann-La Roche Ag Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k.
CA2650295C (en) * 2006-04-26 2015-12-29 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
BRPI0710943A2 (pt) 2006-04-26 2012-06-26 Genentech Inc compostos farmacêuticos
US20100016435A1 (en) 2006-05-16 2010-01-21 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
KR20090077914A (ko) 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CA2662580C (en) 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8399452B2 (en) 2006-10-28 2013-03-19 Methylgene Inc. Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2007333243B2 (en) 2006-12-07 2013-03-14 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
RU2009134223A (ru) 2007-02-15 2011-03-20 Новартис АГ (CH) Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
US20080234332A1 (en) 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US8247397B2 (en) * 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909631B (zh) * 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
RS54230B1 (sr) * 2009-01-08 2015-12-31 Curis Inc. Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
TWI428336B (zh) 2009-10-12 2014-03-01 Hoffmann La Roche Ｐｉ３ｋ抑制劑及ｍｅｋ抑制劑之組合
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
ME02451B (me) * 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
EP3313443B9 (en) 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗

Also Published As

Publication number Publication date
US11654136B2 (en) 2023-05-23
US20190091211A1 (en) 2019-03-28
EA201301114A1 (ru) 2014-04-30
ME02451B (me) 2016-09-20
HRP20191091T1 (hr) 2019-09-20
EP3111938A1 (en) 2017-01-04
MX340577B (es) 2016-07-13
ES2733128T3 (es) 2019-11-27
CY1117785T1 (el) 2017-05-17
SG10201602569RA (en) 2016-05-30
US20200215039A1 (en) 2020-07-09
US20220168284A1 (en) 2022-06-02
CA2830822C (en) 2018-10-02
HK1194969A1 (zh) 2014-10-31
JP6275784B2 (ja) 2018-02-07
DK3111938T3 (da) 2019-07-01
BR112013025340B1 (pt) 2021-12-21
BR112013025340A2 (pt) 2016-12-13
US10111864B2 (en) 2018-10-30
SMT201900435T1 (it) 2019-09-09
JP2014509653A (ja) 2014-04-21
NZ615586A (en) 2015-02-27
JP2018052987A (ja) 2018-04-05
US11135205B2 (en) 2021-10-05
MX2013011132A (es) 2014-03-12
PL2694075T3 (pl) 2016-09-30
PT2694075T (pt) 2016-07-11
JP6242331B2 (ja) 2017-12-06
US20140243330A1 (en) 2014-08-28
US20170304279A1 (en) 2017-10-26
PT3111938T (pt) 2019-07-10
SG193563A1 (en) 2013-11-29
WO2012135571A1 (en) 2012-10-04
US20130090335A1 (en) 2013-04-11
JP2016188255A (ja) 2016-11-04
RS54903B1 (sr) 2016-10-31
LT3111938T (lt) 2019-06-25
TW201247678A (en) 2012-12-01
US10543197B2 (en) 2020-01-28
CL2013002823A1 (es) 2014-04-11
HRP20160545T1 (hr) 2016-06-17
PE20141382A1 (es) 2014-11-04
KR20180108848A (ko) 2018-10-04
EP2694075A4 (en) 2014-10-01
AU2012236367B2 (en) 2014-10-09
EA022434B1 (ru) 2015-12-30
NZ705039A (en) 2016-03-31
DK2694075T3 (en) 2016-08-01
ME03523B (me) 2020-04-20
KR20140023333A (ko) 2014-02-26
CN103582483A (zh) 2014-02-12
US20160185796A1 (en) 2016-06-30
EP2694075B1 (en) 2016-04-27
SI3111938T1 (sl) 2019-08-30
RS59219B1 (sr) 2019-10-31
CY1121825T1 (el) 2020-07-31
EP3111938B1 (en) 2019-05-08
IL248597A0 (en) 2016-12-29
CN103582483B (zh) 2016-02-17
SMT201600179B (it) 2016-08-31
ZA201307082B (en) 2015-04-29
IL228588A0 (en) 2013-12-31
EA022434B9 (ru) 2016-02-29
EP2694075A1 (en) 2014-02-12
PL3111938T3 (pl) 2019-09-30
KR101902325B1 (ko) 2018-09-28
US8710219B2 (en) 2014-04-29
TWI571469B (zh) 2017-02-21
IL228588A (en) 2016-11-30
ES2577982T3 (es) 2016-07-19
IL248597B (en) 2018-04-30
CN105461736B (zh) 2018-06-12
CA2830822A1 (en) 2012-10-04
ZA201406167B (en) 2015-03-25
US9657032B2 (en) 2017-05-23
AU2012236367A1 (en) 2013-04-18
CN105461736A (zh) 2016-04-06
US9249156B2 (en) 2016-02-02
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
IL237727A0 (en) Inhibitors of phosphoinositide 3-kinase with a zinc-binding group
IL248597A0 (en) A phosphoinositide-3-kinase inhibitor with a zinc binding site
GB2481513B (en) A magazine add-on
ZA201306639B (en) Attachment mechanism for a contaienr
GB201020236D0 (en) A composition for detecting biofilms on viable tissues
EP2611352A4 (en) DISHWASHER
PL2575543T3 (pl) Zestaw do konstruowania stelaża
GB201007327D0 (en) A fireseal
ZA201306307B (en) A fungicidal composition
GB201003609D0 (en) A phantom
GB201002966D0 (en) A bedchair
HUE056022T2 (hu) Eszköz egy fogaskerék rögzítésére
PL2385030T3 (pl) Kompozycja klejowa wolna od emisji
GB2484514B (en) A mechanism
GB201200412D0 (en) A rake
PL2611293T3 (pl) Nowa biocydowa kompozycja
AU332267S (en) A bumper guard
AU332323S (en) A bumper guard
GB201010041D0 (en) Drawer assembly for a vehicle
PH32010000120S1 (en) A rack
GB201116046D0 (en) A cover
GB201116008D0 (en) A kennel
PH32010000289S1 (en) A ballpen
GB201004308D0 (en) New inhibitor compounds